Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
The Lancet. Oncology
|
April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
Jean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2019
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid Tumors
Mark W Kieran, Birgit Geoerger, Ira J Dunkel, et al.
The Oncologist
|
September 20, 2022
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
Adam C Diehl, Lindsay M Hannan, David B Zhen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 11, 2024
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024
Jason Gotlib, Aaron T Gerds, Peter Abdelmessieh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Anesthesia and Analgesia
|
May 22, 2018
Evaluating Patient-Centered Outcomes in Clinical Trials of Procedural Sedation, Part 2 Safety: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research Recommendations
Denham S Ward, Mark R Williams, John W Berkenbosch, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
The Lancet. Oncology
|
April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
Jean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2019
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid Tumors
Mark W Kieran, Birgit Geoerger, Ira J Dunkel, et al.
The Oncologist
|
September 20, 2022
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
Adam C Diehl, Lindsay M Hannan, David B Zhen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 11, 2024
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024
Jason Gotlib, Aaron T Gerds, Peter Abdelmessieh, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 9, 2026
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
Aaron T Gerds, Jason Gotlib, Peter Abdelmessieh, et al.
Anesthesia and Analgesia
|
May 22, 2018
Evaluating Patient-Centered Outcomes in Clinical Trials of Procedural Sedation, Part 2 Safety: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research Recommendations
Denham S Ward, Mark R Williams, John W Berkenbosch, et al.
Page
of 3